Artiva Biotherapeutics, Inc.

For the period ended Sep 30, 2026. Filed Nov 9, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2026 · Filed Nov 9, 2026

ARTV$4.06-3.8%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Statements of Stockholders’ Equity

(in thousands, except share data)

COMMON STOCK · ADDITIONALPAID-IN · ACCUMULATEDOTHERCOMPREHENSIVE · ACCUMULATED · TOTALSTOCKHOLDERS’
	SHARES	AMOUNT	CAPITAL	INCOME (LOSS)	DEFICIT	EQUITY
Balance at December 31, 2025	24,595,550	$3	$440,413	$103	$(330,549)	$109,970
ESPP shares issued	64,768	—	131	—	—	131
Issuance of common stock in connection with restricted stock units, net	56,354	—	(210)	—	—	(210)
Stock-based compensation expense	—	—	1,593	—	—	1,593
Unrealized loss on investments, net	—	—	—	(121)	—	(121)
Net loss	—	—	—	—	(23,516)	(23,516)
Balance at March 31, 2026	24,716,672	$3	$441,927	$(18)	$(354,065)	$87,847
Exercise of stock options	13,310	—	67	—	—	67
ESPP shares issued	3,568	—	7	—	—	7
Public offering of common stock and issuance of pre-funded warrants, net of issuance costs	23,871,526	2	282,722	—	—	282,724
Issuance of common stock in connection with restricted stock units	187,203	—	—	—	—	—
Stock-based compensation expense	—	—	1,865	—	—	1,865
Unrealized loss on investments, net	—	—	—	(3)	—	(3)
Net loss	—	—	—	—	(25,005)	(25,005)
Balance at June 30, 2026	48,792,279	$5	$726,588	$(21)	$(379,070)	$347,502
Exercise of stock options	57,222	—	270	—	—	270
ESPP shares issued	82,939	—	187	—	—	187
Issuance of common stock in connection with restricted stock units	332,818	—	—	—	—	—
Stock-based compensation expense	—	—	2,804	—	—	2,804
Unrealized loss on investments, net	—	—	—	(1,225)	—	(1,225)
Net loss	—	—	—	—	(28,822)	(28,822)
Balance at September 30, 2026	49,265,258	$5	$729,849	$(1,246)	$(407,892)	$320,716

Condensed Statements of Stockholders’ Equity

(in thousands, except share data)

COMMON STOCK · ADDITIONALPAID-IN · ACCUMULATEDOTHERCOMPREHENSIVE · ACCUMULATED · TOTALSTOCKHOLDERS’
	SHARES	AMOUNT	CAPITAL	INCOME (LOSS)	DEFICIT	EQUITY
Balance at December 31, 2024	24,291,607	$3	$433,451	$(129)	$(246,684)	$186,641
Exercise of stock options	26,834	—	138	—	—	138
ESPP shares issued	22,164	—	134	—	—	134
Issuance of common stock in connection with restricted stock units	22,514	—	—	—	—	—
Stock-based compensation expense	—	—	2,052	—	—	2,052
Unrealized gain on investments, net	—	—	—	129	—	129
Net loss	—	—	—	—	(20,311)	(20,311)
Balance at March 31, 2025	24,363,119	$3	$435,775	$—	$(266,995)	$168,783
Issuance of common stock in connection with restricted stock units, net	30,405	—	(39)	—	—	(39)
Stock-based compensation expense	—	—	1,549	—	—	1,549
Unrealized gain on investments, net	—	—	—	2	—	2
Net loss	—	—	—	—	(21,254)	(21,254)
Balance at June 30, 2025	24,393,524	$3	$437,285	$2	$(288,249)	$149,041
ESPP shares issued	54,752	—	99	—	—	99
Issuance of common stock in connection with restricted stock units, net	96,628	—	(104)	—	—	(104)
Stock-based compensation expense	—	—	1,631	—	—	1,631
Unrealized gain on investments, net	—	—	—	85	—	85
Net loss	—	—	—	—	(21,528)	(21,528)
Balance at September 30, 2025	24,544,904	$3	$438,911	$87	$(309,777)	$129,224

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.